The Cancer Immunogram as a Framework for Personalized Immunotherapy in Urothelial Cancer

Bellmunt, 2017, Pembrolizumab as second-line therapy for advanced urothelial carcinoma, N Engl J Med, 376, 1015, 10.1056/NEJMoa1613683 Powles, 2018, Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial, Lancet, 391, 748, 10.1016/S0140-6736(17)33297-X Blank, 2016, Cancer immunology. The “cancer immunogram”, Science, 352, 658, 10.1126/science.aaf2834 Karasaki, 2017, An immunogram for the cancer-immunity cycle: towards personalized immunotherapy of lung cancer, J Thorac Oncol, 12, 791, 10.1016/j.jtho.2017.01.005 Gilboa, 1999, The makings of a tumor rejection antigen, Immunity, 11, 263, 10.1016/S1074-7613(00)80101-6 Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N Engl J Med, 372, 2509, 10.1056/NEJMoa1500596 Iyer, 2017, Mismatch repair (MMR) detection in urothelial carcinoma (UC) and correlation with immune checkpoint blockade (ICB) response, J Clin Oncol, 35, 4511, 10.1200/JCO.2017.35.15_suppl.4511 Lawrence, 2013, Mutational heterogeneity in cancer and the search for new cancer-associated genes, Nature, 499, 214, 10.1038/nature12213 Rosenberg, 2016, Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial, Lancet, 387, 1909, 10.1016/S0140-6736(16)00561-4 Galsky, 2017, 848PD Impact of tumor mutation burden on nivolumab efficacy in second-line urothelial carcinoma patients: exploratory analysis of the phase ii checkmate 275 study, Ann Oncol, 28, v295, 10.1093/annonc/mdx371.003 Sharma, 2017, Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial, Lancet Oncol, 18, 312, 10.1016/S1470-2045(17)30065-7 Mariathasan, 2018, TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells, Nature, 554, 544, 10.1038/nature25501 Teo, 2018, Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers, J Clin Oncol, 36, 1685, 10.1200/JCO.2017.75.7740 Sjodahl, 2017, Molecular classification of urothelial carcinoma: global mRNA classification versus tumour-cell phenotype classification, J Pathol, 242, 113, 10.1002/path.4886 Cancer Genome Atlas Research, 2014, Comprehensive molecular characterization of urothelial bladder carcinoma, Nature, 507, 315, 10.1038/nature12965 Moore, 2010, Why do viruses cause cancer? Highlights of the first century of human tumour virology, Nat Rev Cancer, 10, 878, 10.1038/nrc2961 Al-Shibli, 2008, Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer, Clin Cancer Res, 14, 5220, 10.1158/1078-0432.CCR-08-0133 Sharma, 2007, CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma, Proc Natl Acad Sci U S A, 104, 3967, 10.1073/pnas.0611618104 Chen, 2017, Elements of cancer immunity and the cancer-immune set point, Nature, 541, 321, 10.1038/nature21349 Sweis, 2016, Molecular drivers of the non-T-cell-inflamed tumor microenvironment in urothelial bladder cancer, Cancer Immunol Res, 4, 563, 10.1158/2326-6066.CIR-15-0274 Robertson, 2017, Comprehensive molecular characterization of muscle-invasive bladder cancer, Cell, 171, 10.1016/j.cell.2017.09.007 Korpal, 2017, Evasion of immunosurveillance by genomic alterations of PPARgamma/RXRalpha in bladder cancer, Nat Commun, 8, 103, 10.1038/s41467-017-00147-w Allen, 1993, Expression of basic fibroblast growth factor and its receptor in an invasive bladder carcinoma cell line, J Cell Physiol, 155, 368, 10.1002/jcp.1041550218 Siefker-Radtke, 2018, First results from the primary analysis population of the phase 2 study of erdafitinib (ERDA; JNJ-42756493) in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRalt), J Clin Oncol, 36, 4503, 10.1200/JCO.2018.36.15_suppl.4503 Diab, 2018, NKTR-214 (CD122-biased agonist) plus nivolumab in patients with advanced solid tumors: Preliminary phase 1/2 results of PIVOT, J Clin Oncol, 36, 3006, 10.1200/JCO.2018.36.15_suppl.3006 Frederick, 2013, BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma, Clin Cancer Res, 19, 1225, 10.1158/1078-0432.CCR-12-1630 Sundstedt, 2003, Role for IL-10 in suppression mediated by peptide-induced regulatory T cells in vivo, J Immunol, 170, 1240, 10.4049/jimmunol.170.3.1240 Baras, 2016, The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder, Oncoimmunology, 5, e1134412, 10.1080/2162402X.2015.1134412 Mantovani, 2013, Macrophage plasticity and polarization in tissue repair and remodelling, J Pathol, 229, 176, 10.1002/path.4133 Mantovani, 1986, Origin and regulation of tumor-associated macrophages: the role of tumor-derived chemotactic factor, Biochim Biophys Acta, 865, 59 Murdoch, 2007, Expression of Tie-2 by human monocytes and their responses to angiopoietin-2, J Immunol, 178, 7405, 10.4049/jimmunol.178.11.7405 Molon, 2011, Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells, J Exp Med, 208, 1949, 10.1084/jem.20101956 Takeuchi, 2016, Predominance of M2-polarized macrophages in bladder cancer affects angiogenesis, tumor grade and invasiveness, Oncol Lett, 11, 3403, 10.3892/ol.2016.4392 Wang, 2017, Bladder cancer cells induce immunosuppression of T cells by supporting PD-L1 expression in tumour macrophages partially through interleukin 10, Cell Biol Int, 41, 177, 10.1002/cbin.10716 Tavazoie, 2018, LXR/ApoE activation restricts innate immune suppression in cancer, Cell, 172, 10.1016/j.cell.2017.12.026 Balar, 2017, First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study, Lancet Oncol, 18, 1483, 10.1016/S1470-2045(17)30616-2 Mezzadra, 2017, Identification of CMTM6 and CMTM4 as PD-L1 protein regulators, Nature, 549, 106, 10.1038/nature23669 Wolchok, 2017, Overall survival with combined nivolumab and ipilimumab in advanced melanoma, N Engl J Med, 377, 1345, 10.1056/NEJMoa1709684 Sharma P, Callahan MK, Calvo E, et al. Efficacy and safety of nivolumab plus ipilimumab in previously treated metastatic urothelial carcinoma: First results from the phase I/II CheckMate 032 study. Presented at: 2016 SITC Annual Meeting; November 9-13, 2016; National Harbor, MD. Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, 12, 252, 10.1038/nrc3239 Topalian, 2015, Immune checkpoint blockade: a common denominator approach to cancer therapy, Cancer Cell, 27, 450, 10.1016/j.ccell.2015.03.001 Ascierto, 2017, Initial efficacy of anti-lymphocyte activation gene-3 (anti–LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy, J Clin Oncol, 35, 9520, 10.1200/JCO.2017.35.15_suppl.9520 Ascierto, 2017, Checkpoint inhibitors in melanoma and early phase development in solid tumors: what's the future?, J Transl Med, 15, 173, 10.1186/s12967-017-1278-5 Blackburn, 2009, Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection, Nat Immunol, 10, 29, 10.1038/ni.1679 Grosso, 2007, LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems, J Clin Invest, 117, 3383, 10.1172/JCI31184 Riaz, 2017, Tumor and microenvironment evolution during immunotherapy with nivolumab, Cell, 171, 10.1016/j.cell.2017.09.028 Herbst, 2014, Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients, Nature, 515, 563, 10.1038/nature14011 Levy, 2008, Human leukocyte antigen-E protein is overexpressed in primary human colorectal cancer, Int J Oncol, 32, 633 Cohen, 2018, Cancer Res, 78, CT158, 10.1158/1538-7445.AM2018-CT158 Segal, 2018, First-in-human dose escalation of monalizumab plus durvalumab, with expansion in patients with metastatic microsatellite-stable colorectal cancer, J Clin Oncol, 36, 3540, 10.1200/JCO.2018.36.15_suppl.3540 Ferrucci, 2015, Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients, Br J Cancer, 112, 1904, 10.1038/bjc.2015.180 Martens, 2016, Increases in absolute lymphocytes and circulating CD4+ and CD8+ T cells are associated with positive clinical outcome of melanoma patients treated with ipilimumab, Clin Cancer Res, 22, 4848, 10.1158/1078-0432.CCR-16-0249 Martens, 2016, Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab, Clin Cancer Res, 22, 2908, 10.1158/1078-0432.CCR-15-2412 Simeone, 2014, Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma, Cancer Immunol Immunother, 63, 675, 10.1007/s00262-014-1545-8 Marchioni, 2016, The clinical use of the neutrophil to lymphocyte ratio (NLR) in urothelial cancer: a systematic review, Clin Genitourin Cancer, 14, 473, 10.1016/j.clgc.2016.04.008 Powles, 2017, Tumor shrinkage and increased overall survival are associated with improved albumin, neutrophil lymphocyte ratio (NLR) and decreased durvalumab clearance in NSCLC and UC patients receiving durvalumab, J Clin Oncol, 35, 3035, 10.1200/JCO.2017.35.15_suppl.3035 Sharma, 2018, Abstract CT178: Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: efficacy and safety update and association between biomarkers and overall survival in CheckMate 275, Cancer Res, 78, 10.1158/1538-7445.AM2018-CT178 Ornstein, 2018, Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy, Urol Oncol, 36, 405, 10.1016/j.urolonc.2018.02.018 Lin, 2015, Mechanistic basis and clinical relevance of the role of transforming growth factor-beta in cancer, Cancer Biol Med, 12, 385 Roncarolo, 2001, Type 1T regulatory cells, Immunol Rev, 182, 68, 10.1034/j.1600-065X.2001.1820105.x Noguchi, 2017, Temporally distinct PD-L1 expression by tumor and host cells contributes to immune escape, Cancer Immunol Res, 5, 106, 10.1158/2326-6066.CIR-16-0391 Lebrun, 2012, The dual role of TGFbeta in human cancer: from tumor suppression to cancer metastasis, ISRN Mol Biol, 2012, 381428, 10.5402/2012/381428 Jiang, 2015, T-cell exhaustion in the tumor microenvironment, Cell Death Dis, 6, e1792, 10.1038/cddis.2015.162 Shariat, 2001, Preoperative plasma levels of transforming growth factor (1 strongly predict clinical outcome in patients with bladder carcinoma, Cancer, 92, 2985, 10.1002/1097-0142(20011215)92:12<2985::AID-CNCR10175>3.0.CO;2-5 Zhang, 2004, Adenosine acts through A2 receptors to inhibit IL-2-induced tyrosine phosphorylation of STAT5 in T lymphocytes: role of cyclic adenosine 3’,5’-monophosphate and phosphatases, J Immunol, 173, 932, 10.4049/jimmunol.173.2.932 Mittal, 2016, Adenosine 2B receptor expression on cancer cells promotes metastasis, Cancer Res, 76, 4372, 10.1158/0008-5472.CAN-16-0544 Martin, 2017, Mutually exclusive expression of CD73 and PDL1 in tumors from patients (pt) with NSCLC, gastroesophageal (GE) and urothelial bladder carcinoma (UBC), J Clin Oncol, 35, 3079, 10.1200/JCO.2017.35.15_suppl.3079 Gavalas, 2012, VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2, Br J Cancer, 107, 1869, 10.1038/bjc.2012.468 Dickinson, 1994, Quantification of angiogenesis as an independent predictor of prognosis in invasive bladder carcinomas, Br J Urol, 74, 762, 10.1111/j.1464-410X.1994.tb07122.x Petrylak, 2017, Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial, Lancet, 390, 2266, 10.1016/S0140-6736(17)32365-6 Atkins, 2017, IMmotion150: a phase II trial in untreated metastatic renal cell carcinoma (mRCC) patients (pts) of atezolizumab (atezo) and bevacizumab (bev) vs and following atezo or sunitinib (sun), J Clin Oncol, 35, 4505, 10.1200/JCO.2017.35.15_suppl.4505 Zelenay, 2015, Cyclooxygenase-dependent tumor growth through evasion of immunity, Cell, 162, 1257, 10.1016/j.cell.2015.08.015 Wang, 2015, Immunosuppression associated with chronic inflammation in the tumor microenvironment, Carcinogenesis, 36, 1085, 10.1093/carcin/bgv123 Yoshida, 2008, C-reactive protein level predicts prognosis in patients with muscle-invasive bladder cancer treated with chemoradiotherapy, BJU Int, 101, 978, 10.1111/j.1464-410X.2007.07408.x Renner, 2017, Metabolic hallmarks of tumor and immune cells in the tumor microenvironment, Front Immunol, 8, 248, 10.3389/fimmu.2017.00248 Papadopoulos, 2017, CX-1158-101: a first-in-human phase 1 study of CB-1158, a small molecule inhibitor of arginase, as monotherapy and in combination with an anti-PD-1 checkpoint inhibitor in patients (pts) with solid tumors, J Clin Oncol, 35, 3005, 10.1200/JCO.2017.35.15_suppl.3005 Cham, 2008, Glucose deprivation inhibits multiple key gene expression events and effector functions in CD8+ T cells, Eur J Immunol, 38, 2438, 10.1002/eji.200838289 Moon, 2015, Targeting the indoleamine 2,3-dioxygenase pathway in cancer, J Immunother Cancer, 3, 51, 10.1186/s40425-015-0094-9 Yang, 2015, Expression and function analysis of indoleamine 2 and 3-dioxygenase in bladder urothelial carcinoma, Int J Clin Exp Pathol, 8, 1768 Yen, 2009, A novel cancer therapy by skin delivery of indoleamine 2,3-dioxygenase siRNA, Clin Cancer Res, 15, 641, 10.1158/1078-0432.CCR-08-1988 Smith, 2017, Epacadostat plus pembrolizumab in patients with advanced urothelial carcinoma: preliminary phase I/II results of ECHO-202/KEYNOTE-037, J Clin Oncol, 35, 4503, 10.1200/JCO.2017.35.15_suppl.4503 Tabernero, 2018, BMS-986205, an indoleamine 2,3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (NIVO): updated safety across all tumor cohorts and efficacy in pts with advanced bladder cancer (advBC), J Clin Oncol, 36, 4512, 10.1200/JCO.2018.36.15_suppl.4512 Long, 2018, Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: results of the phase 3 ECHO-301/KEYNOTE-252 study, J Clin Oncol, 36, 108, 10.1200/JCO.2018.36.15_suppl.108 Choi, 2009, Differential impact of L-arginine deprivation on the activation and effector functions of T cells and macrophages, J Leukoc Biol, 85, 268, 10.1189/jlb.0508310 Droge, 1988, Plasma glutamate concentration and lymphocyte activity, J Cancer Res Clin Oncol, 114, 124, 10.1007/BF00417824 Weide, 2016, Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab, Clin Cancer Res, 22, 5487, 10.1158/1078-0432.CCR-16-0127 Jiang, 2016, LDH-A promotes malignant progression via activation of epithelial-to-mesenchymal transition and conferring stemness in muscle-invasive bladder cancer, Biochem Biophys Res Commun, 469, 985, 10.1016/j.bbrc.2015.12.078 Pond, 2018, New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab, J Clin Oncol, 36, 413, 10.1200/JCO.2018.36.6_suppl.413 Milstein, 2011, CTLs respond with activation and granule secretion when serving as targets for T-cell recognition, Blood, 117, 1042, 10.1182/blood-2010-05-283770 Heninger, 2015, Augmenting antitumor immune responses with epigenetic modifying agents, Front Immunol, 6, 29 Wrangle, 2013, Alterations of immune response of non-small cell lung cancer with azacytidine, Oncotarget, 4, 2067, 10.18632/oncotarget.1542 Sade-Feldman, 2017, Resistance to checkpoint blockade therapy through inactivation of antigen presentation, Nat Commun, 8, 1136, 10.1038/s41467-017-01062-w Tran, 2016, T-cell transfer therapy targeting mutant KRAS in cancer, N Engl J Med, 375, 2255, 10.1056/NEJMoa1609279 Romero, 2005, Coordinated downregulation of the antigen presentation machinery and HLA class I/beta2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer, Int J Cancer, 113, 605, 10.1002/ijc.20499 Cha, 2014, Improved survival with T cell clonotype stability after anti-CTLA-4 treatment in cancer patients, Sci Transl Med, 6, 238ra70, 10.1126/scitranslmed.3008211 Snyder, 2017, Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: an exploratory multi-omic analysis, PLoS Med, 14, e1002309, 10.1371/journal.pmed.1002309 Rozeman, 2018, Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo), J Clin Oncol, 36, 10.1200/JCO.2018.36.15_suppl.TPS9606 Gao, 2016, Loss of IFN-gamma pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy, Cell, 167, 10.1016/j.cell.2016.08.069 Lesterhuis, 2017, Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity, Nat Rev Drug Discov, 16, 264, 10.1038/nrd.2016.233